Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zile

Showing results (841-850 of 1,060) with videos related to

Pageof 106
Sort By:
Circulation. Heart Failure|September 16, 2015
HDACs Regulate miR-133a Expression in Pressure Overload-Induced Cardiac FibrosisLudivine Renaud, Lillianne G Harris, Santhosh K Mani, et al.
The American Journal of Medicine|September 27, 2013
Digoxin and 30-day all-cause hospital admission in older patients with chronic diastolic heart failureTaimoor Hashim, Shereen Elbaz, Kanan Patel, et al.
Circulation. Heart Failure|August 9, 2017
Health-Related Quality of Life Outcomes in PARADIGM-HFEldrin F Lewis, Brian L Claggett, John J V McMurray, et al.
Journal of Cardiac Failure|May 22, 2026
Baroreflex activation therapy in heart failure - the Barostim-Enabled Neurohormonal Intervention for Improving Treatment of Heart Failure (BENEFIT-HF) trial rationale and designFarooq H Sheikh, William T Abraham, Philip B Adamson, et al.
The American Journal of Cardiology|July 13, 2019
Relation of Lymphangiogenic Factor Vascular Endothelial Growth Factor-D to Elevated Pulmonary Artery Wedge PressureBrian A Houston, Ryan J Tedford, Renee L Baxley, et al.
The New England Journal of Medicine|November 18, 2024
Tirzepatide for Heart Failure with Preserved Ejection Fraction and ObesityMilton Packer, Michael R Zile, Christopher M Kramer, et al.
JAMA Cardiology|August 30, 2024
Effects of Sacubitril/Valsartan on All-Cause Hospitalizations in Heart Failure: Post Hoc Analysis of the PARADIGM-HF and PARAGON-HF Randomized Clinical TrialsHenri Lu, Brian L Claggett, Milton Packer, et al.
Journal of Cardiac Failure|June 19, 2016
Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection FractionParul U Gandhi, Sheryl L Chow, Thomas S Rector, et al.
American Journal of Physiology. Heart and Circulatory Physiology|July 5, 2014
Cardiac-restricted overexpression or deletion of tissue inhibitor of matrix metalloproteinase-4: differential effects on left ventricular structure and function following pressure overload-induced hypertrophyWilliam M Yarbrough, Catalin Baicu, Rupak Mukherjee, et al.
American Journal of Physiology. Heart and Circulatory Physiology|March 11, 2026
Modifying the structural substrate and progression of heart failure with preserved ejection fraction using a regular exercise regimen in pigsStephanie L Samani, Shayne C Barlow, Lisa A Freeburg, et al.
Pageof 106

Showing results (841-850 of 1,060) with videos related to

Sort By:
Pageof 106
Circulation. Heart Failure|September 16, 2015
HDACs Regulate miR-133a Expression in Pressure Overload-Induced Cardiac FibrosisLudivine Renaud, Lillianne G Harris, Santhosh K Mani, et al.
The American Journal of Medicine|September 27, 2013
Digoxin and 30-day all-cause hospital admission in older patients with chronic diastolic heart failureTaimoor Hashim, Shereen Elbaz, Kanan Patel, et al.
Circulation. Heart Failure|August 9, 2017
Health-Related Quality of Life Outcomes in PARADIGM-HFEldrin F Lewis, Brian L Claggett, John J V McMurray, et al.
Journal of Cardiac Failure|May 22, 2026
Baroreflex activation therapy in heart failure - the Barostim-Enabled Neurohormonal Intervention for Improving Treatment of Heart Failure (BENEFIT-HF) trial rationale and designFarooq H Sheikh, William T Abraham, Philip B Adamson, et al.
The American Journal of Cardiology|July 13, 2019
Relation of Lymphangiogenic Factor Vascular Endothelial Growth Factor-D to Elevated Pulmonary Artery Wedge PressureBrian A Houston, Ryan J Tedford, Renee L Baxley, et al.
The New England Journal of Medicine|November 18, 2024
Tirzepatide for Heart Failure with Preserved Ejection Fraction and ObesityMilton Packer, Michael R Zile, Christopher M Kramer, et al.
JAMA Cardiology|August 30, 2024
Effects of Sacubitril/Valsartan on All-Cause Hospitalizations in Heart Failure: Post Hoc Analysis of the PARADIGM-HF and PARAGON-HF Randomized Clinical TrialsHenri Lu, Brian L Claggett, Milton Packer, et al.
Journal of Cardiac Failure|June 19, 2016
Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection FractionParul U Gandhi, Sheryl L Chow, Thomas S Rector, et al.
American Journal of Physiology. Heart and Circulatory Physiology|July 5, 2014
Cardiac-restricted overexpression or deletion of tissue inhibitor of matrix metalloproteinase-4: differential effects on left ventricular structure and function following pressure overload-induced hypertrophyWilliam M Yarbrough, Catalin Baicu, Rupak Mukherjee, et al.
American Journal of Physiology. Heart and Circulatory Physiology|March 11, 2026
Modifying the structural substrate and progression of heart failure with preserved ejection fraction using a regular exercise regimen in pigsStephanie L Samani, Shayne C Barlow, Lisa A Freeburg, et al.
Pageof 106